Here's Why Analysts Are Positive On Prestige Consumer Healthcare Inc. (PBH)

Prestige Consumer Healthcare Inc. (NYSE:PBH) is among the cheap healthcare stocks to buy heading into 2026. As of December 7, Prestige Consumer Healthcare Inc. (NYSE:PBH) is a ‘Buy’ or equivalent, with the majority of the analysts bullish on the stock. With a consensus 1-year median price target of $80, the stock has an upside of nearly 32%.

According to TheFly, Susan Anderson from Canaccord trimmed the price target on Prestige Consumer Healthcare Inc. (NYSE:PBH) to $88 from $100, while keeping a ‘Buy’ rating on the stock, on November 7. The firm noted that the company delivered solid results; however, management claims that sales and earnings outperformed expectations due to Clear Eyes supply timing and the timing of specific retailer orders, which will reduce the numbers for the third quarter.

In the second-quarter results announced on November 6, Prestige Consumer Healthcare Inc. (NYSE:PBH) experienced a 6.1% decline in North American segment revenues, which was offset by a 2.5% rise in international segment revenues. The company remained focused on product innovation and e-commerce strategies, management revealed in the earnings call.

Prestige Consumer Healthcare Inc. (NYSE:PBH) is a New York-based provider of over-the-counter (OTC) health and personal care products. Incorporated in 1996, the company operates through two segments: North American OTC Healthcare and International OTC Healthcare.

While we acknowledge the potential of PBH as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.